Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Adcendo-series-b

More Like This

PR Newswire associated0

Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

PR Newswire associated0

Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team

PR Newswire associated0

Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

ADACEN, Inc., Secures $335 Million in Private Funding